AION
Conditions
Interventions
Intervention 1: Intervention group: receivers of fluoxetine antidepressant, 20 mg daily. Intervention 2: Control group: Receivers of placebo of fluoxetine that are resemble exactly in appearance featu
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Iranian patients Age over 18 years old Patients with diagnosis of AION; non-arteritic type
Exclusion criteria
Exclusion criteria: Pregnancy before or during study Past medical history of cataract, glaucoma ( open or close angle ) congenital eye disease such as cloboma and involvement with disease effecting the central visual field of patient Patients with past medication history of using fluoxetine or other psychological medications including antidepressants Patients suffering from psychological disease Patients who use medications including :arthemeter? astemizol, cisapride, eliglustat, goserelin, isocarboxazide, artemether, leuprolide, linezolid, lumefantrine, methylene blue, phenelzine, pimozide, procarbazine, selegiline, thioridazine, tranylcypromine Patients diagnosed with immunologic and collagen vascular disease Patients with symptoms of or diagnosed with giant cell arteritis and positive CRP more than 3+ or ESR more than 40 Trauma or surgery history of eyes Duration between involvement and interview more than 3 weeks Patients without compliance of using fluoxetine or disagrement of patient to continue accompanying the study Involvement by glaucoma Involvement by cataract Change in depression questionnaire score lower than 1 score in comparison to first and forth visit ( means the poor compliance of patient that has not used fluoxetine Death of patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1)Visual acuity: visual acuity of each patient will measure by snelene chart. 2)Result of VEP test: both time( latency) and voltage parameters of VEP test will measure. Timepoint: 1)Visual acuity: in first visit and 6th month after initiation of treatment 2)VEP: in first visit and 6th month after initiation of treatment. Method of measurement: 1)Visual acuity: snelene chart 2)VEP test by means of VEP device. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)NLR: neutrophil to lymphocyte ratio 2)OC: thickness of retina 3)Perimetry: percent of scotoma in visual field 4)Depression score 5)demographic informations ( age, gender, profession & etc. ). Timepoint: 1)NLR: In first visit and 6th month after initiation of treatment 2)OCT: In first visit and 6th month after initiation of treatment 3)Perimetry: In first visit and 6th month after initiation of treatment 4)Depression score: In first visit and 6th month after initiation of treatment 5)Demographic information ( age, gender, profession & etc.): at first visit. Method of measurement: 1)NLR: CBC diff 2)OCT: OCT device 3)Perimetry: digital perimetry device 4)Depression score: DSM 5 questionnaire 5)Demographic information ( age, gender, profession & etc. ): by means of personal information and epidemiology questionnaires. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Hussein Abbasi
Iran University of Medical Sciences
Outcome results
None listed